We have learned in the past eight years that there is much room for improvement in the selection of medication and treatment of ADHD in children and adolescents.  EEG and qEEG technologies provide identification of neurobiomarkers and are proving to be valuable tools for experienced physicians how know how to interpret the findings and use published research suggestions to avoid medications that are likely to make their patients worse, and consider empirical trials of research-supported medications.  Read the rest of Dr Swayzyna's article published in NeuroConnections Spring 2014 in pdf form here.